Jane Street’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-187,141
| Closed | -$47.4M | – | 11580 |
|
|
2026
Q2 | $49.9M | Buy |
+187,141
| New | +$43.7M | ﹤0.01% | 1431 |
|
|
2026
Q1 | – | Sell |
-21,225
| Closed | -$4.76M | – | 11525 |
|
|
2025
Q4 | $4.53M | Buy |
+21,225
| New | +$4.38M | ﹤0.01% | 3391 |
|
|
2025
Q2 | – | Sell |
-48,299
| Closed | -$7.87M | – | 9574 |
|
|
2025
Q1 | $7.53M | Buy |
48,299
+12,969
| +37% | +$1.85M | ﹤0.01% | 2355 |
|
|
2024
Q4 | $4.86M | Sell |
35,330
-124
| -0.3% | -$16.3K | ﹤0.01% | 2701 |
|
|
2024
Q3 | $5.29M | Buy |
35,454
+19,193
| +118% | +$2.59M | ﹤0.01% | 2766 |
|
|
2024
Q2 | $2.22M | Sell |
16,261
-4,133
| -20% | -$562K | ﹤0.01% | 4386 |
|
|
2024
Q1 | $3.08M | Sell |
20,394
-11,074
| -35% | -$1.58M | ﹤0.01% | 3440 |
|
|
2023
Q4 | $3.96M | Buy |
31,468
+6,751
| +27% | +$673K | ﹤0.01% | 3281 |
|
|
2023
Q3 | $2.31M | Sell |
24,717
-49,698
| -67% | -$4.65M | ﹤0.01% | 3916 |
|
|
2023
Q2 | $6.64M | Buy |
74,415
+60,082
| +419% | +$5.23M | ﹤0.01% | 2433 |
|
|
2023
Q1 | $1.54M | Sell |
14,333
-38,560
| -73% | -$4.41M | ﹤0.01% | 4397 |
|
|
2022
Q4 | $6.46M | Sell |
52,893
-18,392
| -26% | -$2.14M | ﹤0.01% | 2218 |
|
|
2022
Q3 | $7.36M | Buy |
71,285
+30,731
| +76% | +$2.91M | ﹤0.01% | 2119 |
|
|
2022
Q2 | $3.77M | Buy |
40,554
+12,072
| +42% | +$1.14M | ﹤0.01% | 3181 |
|
|
2022
Q1 | $3.34M | Buy |
28,482
+13,861
| +95% | +$1.61M | ﹤0.01% | 3733 |
|
|
2021
Q4 | $1.97M | Buy |
14,621
+7,936
| +119% | +$1.18M | ﹤0.01% | 4530 |
|
|
2021
Q3 | $1.07M | Buy |
+6,685
| New | +$915K | ﹤0.01% | 5784 |
|
|
2021
Q2 | – | Sell |
-4,221
| Closed | -$562K | – | 9741 |
|
|
2021
Q1 | $544K | Buy |
4,221
+267
| +7% | +$40.6K | ﹤0.01% | 6647 |
|
|
2020
Q4 | $659K | Sell |
3,954
-33,769
| -90% | -$5.58M | ﹤0.01% | 5322 |
|
|
2020
Q3 | $5.82M | Sell |
37,723
-2,870
| -7% | -$413K | ﹤0.01% | 1700 |
|
|
2020
Q2 | $6M | Buy |
+40,593
| New | +$5.57M | ﹤0.01% | 1644 |
|
|
2019
Q3 | – | Sell |
-5,420
| Closed | -$624K | – | 5032 |
|
|
2019
Q2 | $624K | Buy |
+5,420
| New | +$649K | ﹤0.01% | 3299 |
|
|
2018
Q2 | – | Sell |
-3,817
| Closed | -$250K | – | 4939 |
|
|
2018
Q1 | $250K | Buy |
+3,817
| New | +$215K | ﹤0.01% | 4221 |
|
|
2017
Q4 | – | Sell |
-9,704
| Closed | -$352K | – | 4537 |
|
|
2017
Q3 | $352K | Buy |
+9,704
| New | +$278K | ﹤0.01% | 3503 |
|
Other funds holding ASND
Jane Street's ASND Position: Q3 2026 in Review
Jane Street sold out of Ascendis Pharma (ASND) in Q3 2026, closing a stake of 187,141 shares — an estimated $47.4M sold.
Jane Street first reported a position in ASND in Q3 2017 and held it in 24 quarters. The position peaked at $49.9M in Q2 2026. 347 funds tracked by Wall St. Rank hold ASND as of Q3 2026.
- Jane Street reported no remaining Ascendis Pharma position as of Q3 2026 after selling out during the quarter.
- Jane Street sold 187,141 Ascendis Pharma shares in Q3 2026, an estimated $47.4M.
- Jane Street first reported a position in Ascendis Pharma in Q3 2017 and held it in 24 quarters.
- Jane Street's Ascendis Pharma position peaked at $49.9M in Q2 2026.
- 347 funds tracked by Wall St. Rank held Ascendis Pharma as of Q3 2026.
Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.